HRS 2018: CABANA Misses Endpoint, Leaving Questions About AF Ablation
Executive Summary
The long-awaited results of the CABANA trial, a large randomized study comparing ablation to drug therapy as a first-line treatment for atrial fibrillation, were presented at the Heart Rhythm Society conference in Boston on May 10. The trial missed its primary endpoint in the "intent to treat" analysis, but showed a significant benefit for ablation in the "as-treated" analysis.
You may also be interested in...
ESC 2017: News Flutter With AFib Data
Atrial fibrillation is always a hot topic at cardiology conferences and this year's European Society of Cardiology Congress in Barcelona was no exception. The meeting highlighted data from a spate of key clinical studies providing more insight into this heart condition, including the CASTLE-AF and CAPTAF studies, which further affirmed the benefits of catheter ablation. Outcomes were also reported from REHEARSE-AF and AFFIRM.
Minute Insight: Abbott Plans Move Into Famous Chicago Skyscraper
Local newspapers in Chicago confirm that Abbott is leasing space in Chicago’s most famous building in an attempt to better serve employees who live closer to the city than its Lake County, IL, campus.
Abbott Announces Another Health Equity Initiative
The Abbott Fund, the company’s charitable foundation, has granted Easterseals $750,000 to fund a three-year pilot project supporting education and community health equity.